Home  |  About us  |  Editorial board  |  Current issue  |  Archives  |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 200Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
QUALITY
Year : 2011  |  Volume : 2  |  Issue : 4  |  Page : 124-128

Quality of clinical trials: A moving target


President, Clininvent Research Pvt. Ltd., Everest Chambers, Mumbai, India

Correspondence Address:
Arun Bhatt
President, Clininvent Research Pvt. Ltd., A-103, Everest Chambers, Marol Naka, Andheri-Kurla Road, Andheri (E), Mumbai - 400 059
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.86880

Rights and Permissions

Quality of clinical trials depends on data integrity and subject protection. Globalization, outsourcing and increasing complexicity of clinical trials have made the target of achieving global quality challenging. The quality, as judged by regulatory inspections of the investigator sites, sponsors/contract research organizations and Institutional Review Board, has been of concern to the US Food and Drug Administration, as there has been hardly any change in frequency and nature of common deficiencies. To meet the regulatory expectations, the sponsors need to improve quality by developing systems with specific standards for each clinical trial process. The quality systems include: personnel roles and responsibilities, training, policies and procedures, quality assurance and auditing, document management, record retention, and reporting and corrective and preventive action. With an objective to improve quality, the FDA has planned new inspection approaches such as risk-based inspections, surveillance inspections, real-time oversight, and audit of sponsor quality systems. The FDA has partnered with Duke University for Clinical Trials Transformation Initiative, which will conduct research projects on design principles, data quality and quantity including monitoring, study start-up, and adverse event reporting. These recent initiatives will go a long way in improving quality of clinical trials.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3821    
    Printed201    
    Emailed3    
    PDF Downloaded1082    
    Comments [Add]    
    Cited by others 4    

Recommend this journal